LRRC15 and central nervous system cancer: In flow cytometry assays using U-87 MG human glioma cells expressing both FAP and LRRC15, the dual-targeted antibody demonstrated increased binding (EC50 = 0.2645 nM vs. 12.68 nM and 0.8885 nM) compared to the FAP-only mAb (EC50 = 12.68 nM) and LRRC15-only mAb (EC50 = 0.8885 nM) controls (Supplementary Figure S7, Supplementary Table S4).